Back to Newsroom

EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China

BOSTON, September 25, 2014 – EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs.  Livzon was also a principal investor in the $36 million private financing round EPIRUS closed in April 2014, prior to becoming a public company.

Click here to read more